HOTH

Hoth Therapeutics Inc

• TipRanks·04/02 21:39

  Hoth Therapeutics Completes Registered Direct Offering Financing

• Reuters·04/02 20:11

  Hoth Therapeutics issues unregistered warrants for 2.86 million shares in private placement

• Reuters·04/02 20:06

  Hoth Therapeutics closes $2 million registered direct offering at $0.70 a share

• PR Newswire·04/02 20:05

  Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

• NASDAQ·04/02 09:32

  Hoth Therapeutics Unveils $2 Mln Direct Offering Of Shares; Eyes Up To $4.4 Mln With Warrants

• Benzinga·04/01 17:56

  Hoth Therapeutics Announces $2M Direct Offering At $0.70/Shr

• Reuters·04/01 17:53

  Hoth Therapeutics prices USD 2 million registered direct offering at USD 0.70/share

• Benzinga·04/01 12:19

  Hoth Therapeutics Announces Over 65% Participants Demonstrate Meaningful Reductions In Pain, Itching In HT-001 Program; HT-001 Well Toleration, No Treatment Discontinuations Seen

• TipRanks·04/01 12:17

  Hoth Therapeutics reports results from ongoing HT-001 program

• Reuters·04/01 12:17

  Hungary approves Hoth HT-001 Phase 2 trial expansion into Europe

• Reuters·04/01 12:15

  HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO TREATMENT DISCONTINUATIONS REPORTED

• Reuters·04/01 12:15

  HOTH THERAPEUTICS INC - ANTICIPATES REGULATORY APPROVALS IN SPAIN AND POLAND WITH SITE ACTIVATIONS EXPECTED SOON

• Reuters·04/01 12:14

  Hoth Therapeutics says HT-001 meets Phase 2 primary endpoint in interim analysis

• Reuters·03/31 22:24

  Hoth Therapeutics says China grants patent for mast cell-targeting oligonucleotide platform